CELLUX
CeO2 Nanoparticles-assisted stem-cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases

Coordinator:
Anna Duarri, Vall d’Hebron Institut de Recerca, Barcelona, Spain

Contact:
Anna.duarri@vhir.org

Partners:
 María Dusinska, NILU-Norwegian Institute for Air Research, Kjeller, Norway
 Luisa Diomedde, Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy
 Alena Sevcu, Technical University of Liberec, Liberec, Czech Republic
 Els Verhoeyen, Centre International de Recherche en Infectiologie (CIRI)/INSERM U1111, Lyon, France
 Ignasi Gispert, Applied Nanoparticles, Barcelona, Spain

Chronic inflammation is now regarded as a major pathogenic pathway common in many different pathologies. Age-related Macular Degeneration (AMD) is a neurodegenerative and complex disorder with multifactorial etiology, currently inevitable and orphan of treatment, that represents a major cause of blindness in people over 50 and affects millions of people worldwide. Its progression is associated to an increase of oxidative stress and inflammatory response in the eye leading to retinal cell death. Recently, a new agent has been added to the group of antioxidant/anti-inflammatory substances with therapeutic properties: cerium oxide nanoparticles (CeO2NPs). CeO2NPs have a unique electronic structure that when reduced to the nanoscale, oxygen defects appear at their surface, behaving as sites for free radical scavenging. Thus, the main objective of CELLUX is to develop a novel pharmaceutical-based CeO2NPs eye drops to treat AMD that in combination with stem cell-based therapeutic strategies, will not only stop degeneration but restore vision.